Ex-GSK CEO, R&D chief Andrew Witty and Moncef Slaoui are jumping into the biotech VC game
Top pharma execs at the marquee companies don’t really retire. Some segue quite naturally into venture capital, where their contacts and heavyweight industry reputations can facilitate the growth of little biotech companies at a time the VC crowd is enjoying a prolonged and popular boom.
This morning two of the biggest names that once dominated GSK for a decade, the newly retired CEO Andrew Witty and longtime R&D chief Moncef Slaoui, mapped out their plans to jump into the biotech venture capital game. Sir Andrew has signed on as a partner at Durham, NC-based Hatteras Venture Partners, while Slaoui has joined the European team at Medicxi.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.